Loading...

ReNeuron Group plc

RENE.L•LSE
Healthcare
Biotechnology
£3.38
£-0.08(-2.17%)

ReNeuron Group plc (RENE.L) Stock Overview

Explore ReNeuron Group plc’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

F

Score: N/A

Key Financials

Market Cap1.9M
P/E Ratio-0.36
EPS (TTM)$-0.09
ROE-0.72%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$0.02

RENE.L Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of ReNeuron Group plc (RENE.L) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.02.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.36 and a market capitalization of 1.9M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for RENE.LStats details for RENE.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for RENE.LAnalyst Recommendations details for RENE.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate that is in the partnering stage in china and outside china for treating stroke disability; and human retinal progenitor cell therapy that is in Phase I/IIa clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized packages of information released by CTX cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. ReNeuron Group plc was founded in 1997 and is headquartered in Pencoed, the United Kingdom.

CEO

Iain Gladstone Ross BSc C.DIR, CH.D

Employees

26

Headquarters

Pencoed Business Park, Pencoed

Founded

2005

Frequently Asked Questions

;